REFERENCES
1. Dona, I., et al., Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol, 2014.24 (3): p. 143-53; quiz 1 p following 153.
2. Dona, I., et al., Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol, 2012. 22 (5): p. 363-71.
3. Kowalski, M.L., et al.,Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs.Allergy, 2013. 68 (10): p. 1219-32.
4. Dona, I., et al.,Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy, 2011. 41 (1): p. 86-95.
5. Zambonino, M.A., et al., Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflammatory drugs in children. Pediatr Allergy Immunol, 2013. 24 (2): p. 151-9.
6. Quiralte, J., et al.,Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol, 1996. 98 (3): p. 678-85.
7. Stevenson, D.D., M. Sanchez-Borges, and A. Szczeklik, Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol, 2001. 87 (3): p. 177-80.
8. Dona, I., et al.,NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. Sci Rep, 2018. 8 (1): p. 16710.
9. Aberer, W., et al., Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy, 2003. 58 (9): p. 854-63.
10. Dona, I., et al., Medical algorithm: Diagnosis and treatment of NSAIDs hypersensitivity. Allergy, 2019.
11. Dona, I., et al., Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy, 2020. 75 (3): p. 561-575.
12. Kowalski, M.L., et al.,Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy, 2019. 74 (1): p. 28-39.
13. Ortega, N., et al.,Practical guidelines for diagnosing hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol, 2014. 24 (5): p. 308-23.
14. Izquierdo-Dominguez, A., et al.,Statement of the Spanish Society of Allergology and Clinical Immunology on Provocation Tests With Aspirin/Nonsteroidal Anti-inflammatory Drugs. J Investig Allergol Clin Immunol, 2020.30 (1): p. 1-13.
15. Bindu, S., S. Mazumder, and U. Bandyopadhyay, Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol, 2020: p. 114147.
16. Conaghan, P.G., A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int, 2012.32 (6): p. 1491-502.
17. https://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/AINE.pdf?x18026.
18. Perez-Sanchez, N., et al.,Evaluation of Subjects Experiencing Allergic Reactions to Non-Steroidal Anti-Inflammatory Drugs: Clinical Characteristics and Drugs Involved. Front Pharmacol, 2020. 11 : p. 503.
19. Brockow, K., et al., EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy, 2019. 74 (1): p. 14-27.
20. Brockow, K., et al.,General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy, 2002. 57 (1): p. 45-51.
21. Goday-Bujan, J.J., et al.,Photoallergic contact dermatitis from dexketoprofen: study of 6 cases. Contact Dermatitis, 2006. 55 (1): p. 59-61.
22. Tavares Almeida, F., et al.,Generalized bullous fixed drug eruption caused by ibuprofen.Contact Dermatitis, 2019. 80 (4): p. 238-239.
23. Campo, P., et al., Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. Allergy, 2013.68 (8): p. 1001-7.
24. Nizankowska-Mogilnicka, E., et al., EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy, 2007. 62 (10): p. 1111-8.
25. Fosbol, E.L., et al., The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people.Pharmacoepidemiol Drug Saf, 2008. 17 (8): p. 822-33.
26. Duong, M., et al., Usage patterns of ’over-the-counter’ vs. prescription-strength nonsteroidal anti-inflammatory drugs in France. Br J Clin Pharmacol, 2014.77 (5): p. 887-95.
27. Valkhoff, V.E., et al.,Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues? BMC Pediatr, 2013. 13 : p. 192.
28. Kidon, M.I., et al., Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children. Pediatrics, 2005. 116 (5): p. e675-80.
29. Kidon, M.I., et al.,Nonsteroidal anti-inflammatory drug hypersensitivity in preschool children. Allergy Asthma Clin Immunol, 2007. 3 (4): p. 114-22.
30. Sanchez-Borges, M. and A. Capriles-Hulett, Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol, 2000.84 (1): p. 101-6.
31. Bagheri, H., et al.,Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data. Drug Saf, 2000. 22 (5): p. 339-49.